Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Nuclear FOXM1 drives chemoresistance in AML.

Literature DB >> 27694928

Nuclear FOXM1 drives chemoresistance in AML.

I Khan¹, M Halasi², M F Zia¹, P Gann³, S Gaitonde³, N Mahmud¹, A L Gartel².

Abstract

Entities: Disease Gene

Mesh：

Substances：

Year: 2016 PMID： 27694928 DOI： 10.1038/leu.2016.270

Source DB: PubMed Journal: Leukemia ISSN： 0887-6924 Impact factor: 11.528

× No keyword cloud information.

17 in total

1. A cell-penetrating ARF peptide inhibitor of FoxM1 in mouse hepatocellular carcinoma treatment.

Authors: Galina A Gusarova; I-Ching Wang; Michael L Major; Vladimir V Kalinichenko; Timothy Ackerson; Vladimir Petrovic; Robert H Costa
Journal: J Clin Invest Date: 2006-12-14 Impact factor: 14.808

2. Nucleophosmin interacts with FOXM1 and modulates the level and localization of FOXM1 in human cancer cells.

Authors: Uppoor G Bhat; Ramasamy Jagadeeswaran; Marianna Halasi; Andrei L Gartel
Journal: J Biol Chem Date: 2011-10-06 Impact factor: 5.157

3. The prognostic landscape of genes and infiltrating immune cells across human cancers.

Authors: Andrew J Gentles; Aaron M Newman; Chih Long Liu; Scott V Bratman; Weiguo Feng; Dongkyoon Kim; Viswam S Nair; Yue Xu; Amanda Khuong; Chuong D Hoang; Maximilian Diehn; Robert B West; Sylvia K Plevritis; Ash A Alizadeh
Journal: Nat Med Date: 2015-07-20 Impact factor: 53.440

Review 4. Regulation of yeast forkhead transcription factors and FoxM1 by cyclin-dependent and polo-like kinases.

Authors: Hiroshi Murakami; Hirofumi Aiba; Makoto Nakanishi; Yuko Murakami-Tonami
Journal: Cell Cycle Date: 2010-08-02 Impact factor: 4.534

5. Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin.

Authors: H Quentmeier; M P Martelli; W G Dirks; N Bolli; A Liso; R A F Macleod; I Nicoletti; R Mannucci; A Pucciarini; B Bigerna; M F Martelli; C Mecucci; H G Drexler; B Falini
Journal: Leukemia Date: 2005-10 Impact factor: 11.528

Review 6. FOX(M1) news--it is cancer.

Authors: Marianna Halasi; Andrei L Gartel
Journal: Mol Cancer Ther Date: 2013-02-26 Impact factor: 6.261

7. Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.

Authors: Eyal C Attar; Jeffrey L Johnson; Philip C Amrein; Gerard Lozanski; Martha Wadleigh; Daniel J DeAngelo; Jonathan E Kolitz; Bayard L Powell; Peter Voorhees; Eunice S Wang; William Blum; Richard M Stone; Guido Marcucci; Clara D Bloomfield; Barry Moser; Richard A Larson
Journal: J Clin Oncol Date: 2012-11-05 Impact factor: 44.544

8. A novel mode of FoxM1 regulation: positive auto-regulatory loop.

Authors: Marianna Halasi; Andrei L Gartel
Journal: Cell Cycle Date: 2009-06-09 Impact factor: 4.534

9. Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia.

Authors: Shujun Liu; Zhongfa Liu; Zhiliang Xie; Jiuxia Pang; Jianhua Yu; Esther Lehmann; Lenguyen Huynh; Tamara Vukosavljevic; Mitsui Takeki; Rebecca B Klisovic; Robert A Baiocchi; William Blum; Pierluigi Porcu; Ramiro Garzon; John C Byrd; Danilo Perrotti; Michael A Caligiuri; Kenneth K Chan; Lai-Chu Wu; Guido Marcucci
Journal: Blood Date: 2007-12-14 Impact factor: 22.113

10. FoxM1 is a general target for proteasome inhibitors.

Authors: Uppoor G Bhat; Marianna Halasi; Andrei L Gartel
Journal: PLoS One Date: 2009-08-12 Impact factor: 3.240

13 in total

Review 1. FOXM1 in Cancer: Interactions and Vulnerabilities.

Authors: Andrei L Gartel
Journal: Cancer Res Date: 2017-06-05 Impact factor: 12.701

2. The antagonistic duality of NPM1 mutations in AML.

Authors: Irum Khan; Andrei L Gartel
Journal: Blood Adv Date: 2022-07-12

3. DRP1 contributes to head and neck cancer progression and induces glycolysis through modulated FOXM1/MMP12 axis.

Authors: Tai-Lin Huang; Chuang-Rung Chang; Chih-Yen Chien; Gong-Kai Huang; Yi-Fan Chen; Li-Jen Su; Hsin-Ting Tsai; Yu-Sheng Lin; Fu-Min Fang; Chang-Han Chen
Journal: Mol Oncol Date: 2022-04-15 Impact factor: 7.449

4. Proteasome inhibitor bortezomib enhances the effect of standard chemotherapy in small cell lung cancer.

Authors: Sanaz Taromi; Florentine Lewens; Ruza Arsenic; Dagmar Sedding; Jörg Sänger; Almut Kunze; Markus Möbs; Joana Benecke; Helma Freitag; Friederike Christen; Daniel Kaemmerer; Amelie Lupp; Mareike Heilmann; Hedwig Lammert; Claus-Peter Schneider; Karen Richter; Michael Hummel; Britta Siegmund; Meike Burger; Franziska Briest; Patricia Grabowski
Journal: Oncotarget Date: 2017-09-23

5. Adrenomedullin-CALCRL axis controls relapse-initiating drug tolerant acute myeloid leukemia cells.

Authors: Jérôme Tamburini; Christian Récher; Clément Larrue; Nathan Guiraud; Pierre-Luc Mouchel; Marine Dubois; Thomas Farge; Mathilde Gotanègre; Claudie Bosc; Estelle Saland; Marie-Laure Nicolau-Travers; Marie Sabatier; Nizar Serhan; Ambrine Sahal; Emeline Boet; Sarah Mouche; Quentin Heydt; Nesrine Aroua; Lucille Stuani; Tony Kaoma; Linus Angenendt; Jan-Henrik Mikesch; Christoph Schliemann; François Vergez; Jean-Emmanuel Sarry
Journal: Nat Commun Date: 2021-01-18 Impact factor: 14.919